updat model post result full year ep estim unchang
modest chang revenu reiter outperform price
although ep estim consensu maintain
full year estim reflect primarili tough compar livestock
well four fewer intern sale day chang account calendar
guidanc set rang estim ep
annual ep estim unchang ep compound-annual-growth-rate
maintain full year revenu estim guidanc set
revenu estim rais
rais top line forecast unchang
abaxi diagnost busi acquir summer approval/launch apoquel china
new product introduct simparico trio flea tick heartworm combo
mab canine/felin pain add upsid potenti
manag set gpm expans goal full year level
model remain line guidanc estim gpm
although quarterli progress may vari part due integr abaxi given
lower gpm also rais annual spend year
sg also rais year continu project annual
oper margin expans lower
tax rate tr lower estim
trend expect continu detail guidanc provid februari
result announc
yesterday bayer announc would exit anim health busi along
number corpor restructur move bayer largest anim
compani estim annual sale approxim product
total over-the-counter topic flea tick liquids/collar advantag seresto bayer also
livestock parasiticid antibiot assum zoeti least look
portfolio offer think bayer product date appear good
pleas see page report import disclosur
rate share outperform base rel attract anim health
market solid outlook top- bottom-lin growth versu market
upsid possibl believ execut prospect move share higher
apoquel cytopoint sale trend
sale compound-annual-growth-rate
ep compound-annual-growth-rate
apoquel cytopoint simparica uptak
greater expect
signific product emerg
restructur provid greater
apoquel cytopoint simparica sale
new oper restructur
influx small new competitor dampen
zoeti inc engag discoveri develop manufactur commerci
anim health medicin vaccin focu livestock companion anim
primari livestock speci cattl beef dairi swine poultri sheep fish
primari companion anim speci dog cat hors zoeti spun
cowen compani
compani data cowen compani
compani data cowen compani
state livestock revenu livestock lc ex companion companion lc ex lc ex revenu contract mfg /human ww lc ex total dog mfg /human revenu cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
state livestock revenu livestock lc ex companion companion lc ex lc ex revenu contract mfg/human ww lc ex total total dog cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
state livestock larg cattl also swine poultri sheep farm fish apoquel simparica new product drive growthtot ahead market growth revenu streamlin driven demand protein livestock lc ex pharmaq farm fish ad companion new product expand pet care companion lc ex -restructur lc ex revenu line market growth upsid possibl new product key apoquel cytopoint simparica contract mfg /human tie former pfizer contractstot ww lc ex strong em demand safe protein beef dairi solid demand asia on-going steadi demand trend toward antibiotic-fre farm fish ad pharmaq sheep othertot speci trend vari geographicallycompanion total dog new product abaxi line extens drive growth nich markettot could even faster given potenti influx new drugscontract mfg /human activ pursuedtot revenu steadi gain post restructur upsid possibl cowen
compani data cowen compani
ceftiofur rev market sinc draxxin rev market sinc anti-infect reflect sku reductionanti-infect exclud growth promot livestock companion anim product pharmaq farm fish vaccin ad revolut price/or competit mainli felin use nich dog simparica oral flea tick launch april eu parasiticid mostli livestock includ fishparasiticid boost pharmaq growth south amer em non-med import includ ractopamin phase shared-us antibioticsoth product apoquel dermat dog expand acut use cytopoint canin atop dermat inject total compani target pharma rimadyl abbott ah sileo nexvet mab pharma undisclos pipelin product could boost diagnost genet test iv fluid embrex anim hlth diagnost mainli companion anim close product assum small bolt-on acquisitionscontract product suppli agreementstot fx boost less cowen
compani data cowen compani
compani data cowen compani
state livestock revenu livestock lc ex companion companion lc ex lc ex revenu contract mfg/human ww lc ex total total dog cowen
compani data cowen compani
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio discount cash flow
competit dynam global potenti regulatori delay reject failur
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk price includ abil re-suppli apoquel success pipelin
product weather/diseas risk busi success independ compani
